Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2014-09-10

FDA Approved: CONTRAVE EXTENDED-RELEASE — Original Application (Nalpropion Pharmaceuticals LLC)

View source ↗

Summary

FDA approved CONTRAVE EXTENDED-RELEASE (naltrexone hydrochloride and bupropion hydrochloride) under an original application for chronic weight management in adu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CONTRAVE EXTENDED-RELEASE (Naltrexone hydrochloride and bupropion hydrochloride)

Snippet

ORIG AP for CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)